Elimusertib (Synonyms: BAY 1895344)

Name: Elimusertib
Brand: MedChemExpress
SKU: HY-101566
Rating: 5.0 (15 reviews)

Cat. No.: HY-101566 Purity: 99.73%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC₅₀ of 7 nM. Elimusertib has anti-tumor activity. Elimusertib can be used for the research of solid tumors and lymphomas.

For research use only. We do not sell to patients.

CAS No. : 1876467-74-1

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 15 publication(s) in Google Scholar

Other Forms of Elimusertib:

15 Publications Citing Use of MCE Elimusertib

Bio/Physico-chemical Assay

Cell Proliferation/Viability Assay

: Elimusertib purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2025 Feb;57(1):167-183. [Abstract]; Effects of Elimusertib on p-BRCA1 (s1423), BRCA1, and RAD51 protein levels. The cells were treated with 0.2 μM Elimusertib for 24 h, and Western blotting was used to detect protein expression. GAPDH was used as the internal control. All FHIT-deficient cells are marked in red.

: Elimusertib purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 May 6:102129. [Abstract]; Comparison of synergy scores for cisplatin by target drug. The Bliss score was calculated using SynergyFinder to evaluate the synergistic effects of BAY1895344 (0.01 μM; 5 days), AZD7762, EPZ015666, or everolimus in combination with cisplatin across 27 OSCC organoids, comprising 10 normal-like, 8 dense, and 9 grape-like subtypes.

: Elimusertib purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2024 Mar;25(3):1469-1489. [Abstract]; Cell viability assays in HCT116 and HT-29 cancer cells cultured at pH 7.4 or 6.5, and treated with the indicated doses of ATRi Elimusertib (0.03-1 μM) for 72 h.

: Elimusertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 24;15(1):9195. [Abstract]; PIDD1−/− HeLa cells transfected with indicated FLAG-PIDD1 variants with or without ATR inhibitor BAY 1895344 (BAY, 0.75 mM)were harvested at 24 h, immunoprecipitated with anti-PIDD1 pT788 antibody, and analyzed by western blot.

: Elimusertib purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2023 May:211:115494. [Abstract]; Elimusertib (10 μM; 1 h) pretreatment inhibits Ara-C-induced p38 MAPK phosphorylation but does not inhibit AKT dephosphorylation.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ATM/ATR Isoform Specific Products:

View All Isoforms

ATM ATR TRRAP

Biological Activity
Purity & Documentation
References
Customer Review

Description

Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC₅₀ of 7 nM. Elimusertib has anti-tumor activity^[1]^[2]. Elimusertib can be used for the research of solid tumors and lymphomas^[3].

IC₅₀ & Target^[1]

ATR

7 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.09 μM Compound: BAY1895344	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay	[PMID: 35191694]
HEK293	IC₅₀	> 10 μM Compound: BAY-1895344	Inhibition of recombinant human ERG stably expressed in HEK293 cells at -80 mV by whole cell voltage clamp method Inhibition of recombinant human ERG stably expressed in HEK293 cells at -80 mV by whole cell voltage clamp method	[PMID: 32502336]
HT-29	IC₅₀	160 nM Compound: BAY-1895344	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 4 days by crystal violet staining based assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 4 days by crystal violet staining based assay	[PMID: 32502336]
HT-29	IC₅₀	36 nM Compound: BAY-1895344	Inhibition of ATR in human HT-29 cells assessed as reduction in histone H2AX phosphorylation measured after 30 mins by immunofluorescence cytometric assay Inhibition of ATR in human HT-29 cells assessed as reduction in histone H2AX phosphorylation measured after 30 mins by immunofluorescence cytometric assay	[PMID: 32502336]
LoVo	IC₅₀	0.041 μM Compound: 5; BAY1895334	Antiproliferative activity against human LoVo cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human LoVo cells incubated for 72 hrs by CCK-8 assay	[PMID: 37130473]
LoVo	IC₅₀	27 nM Compound: 4	Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo assay Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo assay	[PMID: 38299539]
LoVo	IC₅₀	71 nM Compound: BAY-1895344	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability measured after 4 days by crystal violet staining based assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability measured after 4 days by crystal violet staining based assay	[PMID: 32502336]
MCF7	IC₅₀	35 nM Compound: BAY-1895344	Inhibition of PI3K/AKT/mTOR signaling pathway in human MCF7 cells assessed as reduction in AKT phosphorylation at Ser473 residues measured after 30 mins by HTRF assay Inhibition of PI3K/AKT/mTOR signaling pathway in human MCF7 cells assessed as reduction in AKT phosphorylation at Ser473 residues measured after 30 mins by HTRF assay	[PMID: 32502336]
SU-DHL-8	IC₅₀	9 nM Compound: 8	Antiproliferative activity against human SU-DHL-8 cells measured after 72 to 96 hrs by CellTiter-Glo cell viability assay Antiproliferative activity against human SU-DHL-8 cells measured after 72 to 96 hrs by CellTiter-Glo cell viability assay	[PMID: 33135887]
SU-DHL-8	IC₅₀	9 nM Compound: BAY-1895344	Antiproliferative activity against human SUDHL8 cells assessed as reduction in cell viability measured after 4 days by celltiter-glo luminescent assay Antiproliferative activity against human SUDHL8 cells assessed as reduction in cell viability measured after 4 days by celltiter-glo luminescent assay	[PMID: 32502336]

In Vitro

Elimusertib potently inhibits the proliferation of a broad spectrum of human tumor cell lines with a median IC₅₀ of 78 nM^[1].
Elimusertib potently suppresses hydroxyurea-induced H2AX phosphorylation (IC₅₀: 36 nM)^[1].
Elimusertib shows good selectivity against mTOR (ratio of IC₅₀ values: mTOR/ATR 61)^[3].
Elimusertib reveals high selectivity against other related kinases, such as DNA-PK (IC₅₀: 332 nM), ATM (IC₅₀: 1420 nM), and PI3K (IC₅₀: 3270 nM)^[3].
Elimusertib has potent antiproliferative activity against various cancer cell lines in vitro, 25 for example in the CRC cell lines HT-29 (IC₅₀: 160 nM) and LoVo (IC₅₀: 71 nM), and in the B-cell lymphoma cell line SU-DHL-8 (IC₅₀: 9 nM)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Elimusertib shows potent anti-tumor efficacy in monotherapy in a variety of xenograft models of ovarian and colorectal cancer, and causes complete tumor remission in mantle cell lymphoma models^[2].
Elimusertib (50 mg/kg; p.o.; b.i.d.; 3 days on/4 days off; for 11 days) exhibits strong antitumor efficacy in the ATM-mutated SU-DHL-8 (ATM K1964E) human GCB-DLBCL cell line derived xenograft model in mice^[3].
Elimusertib (20 mg/kg, and 10 mg/kg from day 14; p.o.; daily; 2 days on/5 days off; for 42 days) in combination with Carboplatin (40 mg/kg; i.p.; daily; 1 day on/6 days off) results in synergistic antitumor activity in the platinum-resistant ATM protein low expressing CR5038 human CRC PDX model in NOD/SCID mice^[3].
Elimusertib exhibits moderate oral bioavailability (rat 87%, dog 51%) following oral administration (rat and dog 0.6-1 mg/kg)^[3].
Elimusertib exhibits terminal elimination half-lives (mouse 0.17 h, rat 1.3 and, dog 1.0 h) due to plasma clearance (3.5, 1.2, and 0.79 L/h/kg respectively) following intravenous administration (mouse, rat and dog 0.3-0.5 mg/kg)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female C.B-17 SCID mice, SU-DHL-8 GCB-DLBCL xenograft model^[3]
Dosage:	50 mg/kg
Administration:	Oral administration, b.i.d., 3 days on/4 days off, for 11 days
Result:	Inhibited tumor area.

Animal Model:	Male Wistar rats^[3]
Dosage:	0.3-0.5 mg/kg for i.v.; 0.6-1 mg/kg for oral (Pharmacokinetic Analysis)
Administration:	Intravenous injection and oral administration
Result:	Oral bioavailability (87%), T_1/2 (1.3 h).

Animal Model:	Female beagle dogs^[3]
Dosage:	0.3-0.5 mg/kg for i.v.; 0.6-1 mg/kg for oral (Pharmacokinetic Analysis)
Administration:	Intravenous injection and oral administration
Result:	Oral bioavailability (51%), T_1/2 (1.0 h).

Molecular Weight

375.43

Formula

C₂₀H₂₁N₇O

CAS No.

1876467-74-1

Appearance

Solid

Color

Light yellow to yellow

SMILES

CN1N=CC=C1C2=C(C=CN=C3C4=CC=NN4)C3=NC(N5[C@H](C)COCC5)=C2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 5.4 mg/mL (14.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6636 mL	13.3181 mL	26.6361 mL
5 mM	0.5327 mL	2.6636 mL	5.3272 mL
10 mM	0.2664 mL	1.3318 mL	2.6636 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.09 mg/mL (2.90 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.09 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.9 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.89 mg/mL (2.37 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 0.89 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.9 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 4 mg/mL (10.65 mM); Suspended solution; Need ultrasonic and adjust pH to 3 with HCl

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.91%

Select Batch:

Data Sheet (284 KB) SDS (393 KB)

COA (255 KB) HNMR (221 KB) LCMS (122 KB)

Handling Instructions (2659 KB)

References

[1]. Ulrich T. Luecking, et al. Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement.

[2]. Antje Margret Wengner, et al. Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement

[3]. Ulrich Lücking, et al. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem. 2020 Jul 9;63(13):7293-7325. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6636 mL	13.3181 mL	26.6361 mL	66.5903 mL
	5 mM	0.5327 mL	2.6636 mL	5.3272 mL	13.3181 mL
	10 mM	0.2664 mL	1.3318 mL	2.6636 mL	6.6590 mL

Elimusertib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Elimusertib (Synonyms: BAY 1895344)

Customer Review

Other Forms of Elimusertib:

15 Publications Citing Use of MCE Elimusertib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ATM/ATR Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Elimusertib Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Elimusertib (Synonyms: BAY 1895344)

Customer Review

Other Forms of Elimusertib:

Elimusertib Related Antibodies

15 Publications Citing Use of MCE Elimusertib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ATM/ATR Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Elimusertib Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Elimusertib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report